T 0505/20 (Lipid formulations for nucleic acid delivery/ARBUTUS BIOPHARMA CORPORATION) of 29.08.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T050520.20230829
- Date of decision
- 29 August 2023
- Case number
- T 0505/20
- Petition for review of
- -
- Application number
- 09731866.1
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Novel lipid formulations for nucleic acid delivery
- Applicant name
- Arbutus Biopharma Corporation
- Opponent name
- Merck Sharp & Dohme Corporation
Moderna Therapeutics, Inc. - Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 113(1)European Patent Convention R 111(2)Rules of procedure of the Boards of Appeal Art 11
- Keywords
- Appealed decision - reasoned (no)
Right to be heard - substantial procedural violation (yes)
Remittal - fundamental deficiency in first-instance proceedings (yes) - Catchword
- -
- Cited cases
- T 2475/17
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution.
3. The appeal fees of appellants I and II are reimbursed under Rule 103(1)(a) EPC. The appeal fee of the respondent is reimbursed under Rule 103(1)(b) EPC.